Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abiraterone in CRPC Post-Ketoconazole
NCT01199146Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2010
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Abiraterone Acetate Tablets (I) in castration-resistant prostate cancer (CRPC), sponsored by University of California, San Francisco. Primary endpoint: Preliminary Evidence of Efficacy of Abiraterone Acetate at 12 weeks. Started Sep 2010; status: completed.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT01199146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01199146.